Cas No.: | 1703768-74-4 |
Chemical Name: | Vipivotide tetraxetan Ligand-Linker Conjugate |
Synonyms: | PSMA-617 Linker;Vipivotide tetraxetan Linker;JUN68744;(((S)-5-((S)-2-((1r,4S)-4-(aminomethyl)cyclohexane-1-carboxamido)-3-(naphthalen-2-yl)propanamido)-1-carboxypentyl)carbamoyl)-L-glutamic acid;Vipivotide tetraxetan Ligand-Linker Conjugate |
SMILES: | O=C(C1CCC(CN)CC1)N[C@H](C(NCCCC[C@@H](C(=O)O)NC(N[C@H](C(=O)O)CCC(=O)O)=O)=O)CC1C=CC2C=CC=CC=2C=1 |
Formula: | C33H45N5O9 |
M.Wt: | 655.738508939743 |
Purity: | >98% |
Sotrage: | -20 |
Publication: | [1]. Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946. |
Description: | Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is composed of a linker and Glutamate-urea-Lysine, can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine is is the selective pharmacophore to bind to prostate specific membrane antigen (PSMA). |